CoChat

Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness

Open access
Anderson, Sarah L., Trujillo, Jennifer M. · 2016 · Therapeutic Advances in Chronic Disease

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Lixisenatide is a once-daily GLP-1 RA that has been evaluated in the GetGoal clinical trial program and has demonstrated efficacy and tolerability across a spectrum of patients. The feature that most distinguishes lixisenatide from other GLP-1 RAs is its ability to substantially reduce postprandial glucose (PPG) for the meal immediately following injection. Because of its positive effects on PPG, lixisenatide is being considered as a replacement for prandial insulin, and a fixed dose combination product containing lixisenatide and basal insulin is in development. Lixisenatide is a promising new addition to the antidiabetic armamentarium, but due to the lack of real-world experience with the drug, its exact place in therapy is unknown.

Overview

Integrity signals

Registry

Crossref · 10.1177/2040622315609312

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 8

  1. Becker R., 2010, Diabetologia, 53, S339
  2. Brigham and Women’s Hospital (2015) No increased cardiovascular risk detected for new diabetes medication, press release, 8 June. Available at: http://www.brighamandwomens.org/about_bwh/publicaffairs/news/pressreleases/PressRelease.aspx?PageID=%202082 (accessed 24 August 2015).
  3. Distiller L., 2008, Diabetes, 57
  4. Gomez-Huelgas R., 2014, Diabetes, 63, A254
  5. Liu Y., 2009, Diabetes, 59, A149
  6. Liu Y., 2010, Diabetes, 59
  7. Seino Y., 2012, J Diabetes Investig, 3
  8. Zealand Pharma (2015) Zealand informs of updates given by Sanofi on Lyxumia® and LixiLan on an IR thematic conference call on diabetes, Press release no. 4/2015, 9 June. Available at: https://globenewswire.com/news-release/2015/06/09/743262/0/en/files/346068/0/PR%2004–15_0906%20-%20Updates%20by%20Sanofi%20on%20Lyxumia%20and%20Lixilan%20-%20ENG_Final.pdf (accessed 24 August 2015).

Cited by

See all 38

Metadata

Authors
Anderson, S. L., & Trujillo, J. M.
Affiliations
University of Colorado Anschutz (US)
Corresponding author
Trujillo, Jennifer M.
Venue
Therapeutic Advances in Chronic Disease
Published
2015-10-07
Volume
7
Issue
1
Pages
4-17
ISSN
  • 2040-6223 (ISSN-L)
  • 2040-6231
OpenAlex
W2409754321
Cited by
36
References
27
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 4
FWCI
0.60
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Chronic Disease (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
lixisenatide, type 2 diabetes, GLP-1 receptor agonists, glycemic control, postprandial blood glucose, drug tolerability, antidiabetic therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. https://app.cochat.ai/papers/10.1177/2040622315609312
The paper
Anderson, S. L., & Trujillo, J. M. (2016). Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622315609312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.